Louise Bjerregaard

•MD, PhD •Postdoctoral Research Fellow at Beth Israel Deaconess Medical Center and Harvard Medical School

[Louise Bjerregaard @Bjerregaard91]

Honored to join the podcast “In the Thick of It” by the Hypertrophic Cardiomyopathy Society to discuss our recent work on beta blockers and calcium channel blockers in non-obstructive HCM.
#HCM #hcmsociety

[Hypertrophic Cardiomyopathy Medical Society @hcmsociety]

Beta Blockers:New Evidence in Non-Obstructive HCM Care. The latest episode of “In the Thick of It,”an HCMS podcast sponsored by Cytokinetics.Essential for those moving beyond expert opinion to evidence-based, personalized care https://t.co/fMMHf3eMPN
#hcmpodcast #HCM #hcmsociety

[Louise Bjerregaard @Bjerregaard91]

Appreciate the comments - glad to see our study sparking discussion 🫀

[John Mandrola, MD @drjohnm]

I realize beta-blockers have not been shown beneficial in non-obstructive HCM, but, they are commonly prescribed here and in HFpEF. I like this study. It shows clearly that BB worsen exercise capacity.

BB have very selective indications. I am not sure why they are popular

[Louise Bjerregaard @Bjerregaard91]

Our RCT comparing bisoprolol and verapamil in non-obstructive HCM is now published in #JACC ✨

- Bisoprolol: ↓ pVO₂, ↑ NT-proBNP & ↓ KCCQ
- Verapamil: No change in pVO₂ & KCCQ, ↓ NT-proBNP

🔗https://t.co/NJ1hyT5lsg

#HCM #Clinicaltrial

[Louise Bjerregaard @Bjerregaard91]

In obstructive #HCM, #pVO2, #NYHA, and #KCCQ don’t always align!

Weak correlations and frequent patient-level discordance raise considerations for optimal metric selection in clinical practice and clinical trial design.

🔗https://t.co/6tNlxWYDfj

[Department of Cardiology Research AUH @AUHCardio]

Thank you @DCAcademyDK for an amazing #dcasummermeeting23 ☀️

We already look forward to next year’s meeting 🫀